Crescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeting

SALT LAKE CITY, Utah,  Oct. 3, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that four poster presentations on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 11-16, 2016 in Washington, D.C.  Vectra DA is the first and only multi-biomarker […]

Read More

Crescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress

Three Studies Demonstrate the Utility of Vectra DA to Help Predict Treatment Response and Remission in Patients with RA SALT LAKE CITY, Utah, June 10, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that new data on the use of Vectra® DA test to predict treatment response in […]

Read More

Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis

myVectraTM Enables Secure Access to Vectra® DA Test Results SOUTH SAN FRANCISCO, Calif., May 11, 2016 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that it has launched a new web-based portal called myVectra for patients with rheumatoid arthritis (RA).  myVectra provides patients with easy access to their Vectra […]

Read More

United States Patent and Trademark Office Grants Patent for Vectra® DA

SALT LAKE CITY, Dec. 1, 2015 (GLOBE NEWSWIRE) – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent No. 9,200,324. The patent, which is expected to expire in 2031, provides intellectual property protection for Crescendo Bioscience’s Vectra® DA […]

Read More